Chemical Compound Review:
Recentin 4-[(4-fluoro-2-methyl-1H- indol-5-yl)oxy]-6...
Synonyms:
Cadiranib, Cediranib, QCR-93, SureCN63147, Kinome_3318, ...
- AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Takeda, M., Arao, T., Yokote, H., Komatsu, T., Yanagihara, K., Sasaki, H., Yamada, Y., Tamura, T., Fukuoka, K., Kimura, H., Saijo, N., Nishio, K. Clin. Cancer Res. (2007)
- Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. Chen, E., Jonker, D., Gauthier, I., MacLean, M., Wells, J., Powers, J., Seymour, L. Clin. Cancer Res. (2009)
- The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Gomez-Rivera, F., Santillan-Gomez, A.A., Younes, M.N., Kim, S., Fooshee, D., Zhao, M., Jasser, S.A., Myers, J.N. Clin. Cancer Res. (2007)
- Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Curwen, J.O., Musgrove, H.L., Kendrew, J., Richmond, G.H., Ogilvie, D.J., Wedge, S.R. Clin. Cancer Res. (2008)